Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Midostaurin - Novartis Oncology

Drug Profile

Midostaurin - Novartis Oncology

Alternative Names: 4-N-benzoyl staurosporine; Benzoylstaurosporine; CGP-41251; N-benzoyl-staurosporine; PKC-412; PKC-412A; Rydapt

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Massachusetts General Hospital; Mayo Clinic; National Cancer Institute (USA); Novartis; Novartis Oncology; Ohio State University Comprehensive Cancer Center
  • Class Antineoplastics; Carbazoles; Eye disorder therapies; Indole alkaloids; Skin disorder therapies; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Protein kinase C inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Systemic mastocytosis
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Acute myeloid leukaemia; Systemic mastocytosis
  • No development reported Rectal cancer
  • Discontinued Acute biphenotypic leukaemia; Colorectal cancer; Diabetic macular oedema; Gastrointestinal stromal tumours; Multiple myeloma

Most Recent Events

  • 08 Jun 2023 Efficacy data from a phase II trial in Acute myeloid leukaemia presented at the 28th Congress of the European Haematology Association (EHA-2023)
  • 10 Dec 2022 Pharmacodynamics and efficacy data from a phase II trial in Acute myeloid leukemia presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
  • 14 Nov 2022 Novartis Pharmaceuticals completes phase-II trial in Acute myeloid leukaemia (Newly diagnosed, Combination therapy) in Hong Kong, South Korea, Russia, Taiwan, Thailand, Vietnam and Japan (PO) (NCT03280030)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top